| Objective: To explore the efficacy and safety of using Wuzhi capsule to increase the blood concentration of tacrolimus in the treatment of idiopathic membranous nephropathy.Methods: A total of 58 patients with idiopathic membranous nephropathy diagnosed by renal biopsy in the First Hospital of China Medical University from January 2018 to December 2018,were enrolled in the study and received either tacrolimus monotherapy(n=27)or combined therapy of tacrolimus and Wuzhi capsule(n=31).There was no significant difference in basic data between the two groups.The blood concentration of tacrolimus and the indexes of urine routine,24-hour urinary protein quantity,liver fuction and renal function after 6 months treatment were monitored.The dose and time to reach the standard blood concentration of tacrolimus and treatment efficacy and safety were compared between the two groups.Results: Compared with the monotherapy group,the combined therapy group had lower target doses(P =0.007),a shorter time(P =0.007)to the target blood concentration of tacrolimus,and a higher 3-month renal remission rate(P =0.034).There was no significant difference between the incidence of adverse effects observed in the two groups(P >0.05).Conclusion: The combination of Wuzhi capsule and tacrolimus in the treatment of idiopathic membranous nephropathy can reduce the dose and time required to reach the standard blood concentration of tacrolimus,and may induce faster renal remission without increasing adverse effects. |
PDF Full Text Request